PD-1 inhibitor-augmented HAIC-TKI therapy in hepatocellular carcinoma with portal vein tumor thrombosis: real-world survival benefits, safety, and subgroup-specific efficacy.

Front Immunol · 2025 · PMC12198130 · PMID 40574845

Europe PMC DOI

hedged sentences

0.0760

closest p · 1.5× alpha

0.0760

boldest claim

The sentences

showed a trendP =0.076so close (0.05 < p ≤ 0.1)

In Vp4 PVTT patients, pre-PSM analysis showed a trend toward improved survival in the HTP group (13.3 vs. 11.4 months; HR=0.64; 95% CI: 0.39-1.05; P =0.076), which became statistically significant post-PSM (15.3 vs. 9.3 months; HR=0.51; 95% CI: 0.26-0.98; P =0.040).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Although the difference in values did not reach statistical significance, there is a need for clinical vigilance for higher risk of toxicity.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.